1
|
Kammoun HL, Allen TL, Henstridge DC, Barre S, Coll RC, Lancaster GI, Cron L, Reibe S, Chan JY, Bensellam M, Laybutt DR, Butler MS, Robertson AAB, O'Neill LA, Cooper MA, Febbraio MA. Evidence against a role for NLRP3-driven islet inflammation in db/db mice. Mol Metab 2018; 10:66-73. [PMID: 29478918 PMCID: PMC5985230 DOI: 10.1016/j.molmet.2018.02.001] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Accepted: 02/01/2018] [Indexed: 12/30/2022] Open
Abstract
Objectives Type 2 diabetes (T2D) is associated with chronic, low grade inflammation. Activation of the NLRP3 inflammasome and secretion of its target interleukin-1β (IL-1β) have been implicated in pancreatic β cell failure in T2D. Specific targeting of the NLRP3 inflammasome to prevent pancreatic β cell death could allow for selective T2D treatment without compromising all IL-1β-associated immune responses. We hypothesized that treating a mouse model of T2D with MCC950, a compound that specifically inhibits NLRP3, would prevent pancreatic β cell death, thereby preventing the onset of T2D. Methods Diabetic db/db mice were treated with MCC950 via drinking water for 8 weeks from 6 to 14 weeks of age, a period over which they developed pancreatic β cell failure. We assessed metabolic parameters such as body composition, glucose tolerance, or insulin secretion over the course of the intervention. Results MCC950 was a potent inhibitor of NLRP3-induced IL-1β in vitro and was detected at high levels in the plasma of treated db/db mice. Treatment of pre-diabetic db/db mice with MCC950, however, did not prevent pancreatic dysfunction and full onset of the T2D pathology. When examining the NLRP3 pathway in the pancreas of db/db mice, we could not detect an activation of this pathway nor increased levels of its target IL-1β. Conclusions NLRP3 driven-pancreatic IL-1β inflammation does not play a key role in the pathogenesis of the db/db murine model of T2D. Inhibition of NLRP3 via MCC950 in db/db mice did not improve glucose tolerance. MCC950 treatment did not prevent beta cell loss of function. Expression of IL1beta and NLRP3 does not appear increased in db/db islets. We conclude against a role for NLRP3 in db/db pancreatic dysfunction.
Collapse
Affiliation(s)
- H L Kammoun
- Cellular and Molecular Metabolism Laboratory, Baker Heart & Diabetes Institute, Melbourne, Australia.
| | - T L Allen
- Cellular and Molecular Metabolism Laboratory, Baker Heart & Diabetes Institute, Melbourne, Australia
| | - D C Henstridge
- Cellular and Molecular Metabolism Laboratory, Baker Heart & Diabetes Institute, Melbourne, Australia
| | - S Barre
- Cellular and Molecular Metabolism Laboratory, Baker Heart & Diabetes Institute, Melbourne, Australia
| | - R C Coll
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
| | - G I Lancaster
- Cellular and Molecular Metabolism Laboratory, Baker Heart & Diabetes Institute, Melbourne, Australia
| | - L Cron
- Division of Diabetes & Metabolism, Garvan Institute of Medical Research, Sydney, Australia
| | - S Reibe
- Division of Diabetes & Metabolism, Garvan Institute of Medical Research, Sydney, Australia
| | - J Y Chan
- Division of Diabetes & Metabolism, Garvan Institute of Medical Research, Sydney, Australia
| | - M Bensellam
- Division of Diabetes & Metabolism, Garvan Institute of Medical Research, Sydney, Australia
| | - D R Laybutt
- Division of Diabetes & Metabolism, Garvan Institute of Medical Research, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - M S Butler
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
| | - A A B Robertson
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
| | - L A O'Neill
- Inflammation research, Trinity Biomedical Sciences Institute, Dublin, Ireland
| | - M A Cooper
- Institute for Molecular Bioscience, The University of Queensland, St Lucia, Australia
| | - M A Febbraio
- Cellular and Molecular Metabolism Laboratory, Baker Heart & Diabetes Institute, Melbourne, Australia; Division of Diabetes & Metabolism, Garvan Institute of Medical Research, Sydney, Australia; St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
| |
Collapse
|
3
|
Krishnan SM, Dowling JK, Ling YH, Diep H, Chan CT, Ferens D, Kett MM, Pinar A, Samuel CS, Vinh A, Arumugam TV, Hewitson TD, Kemp-Harper BK, Robertson AAB, Cooper MA, Latz E, Mansell A, Sobey CG, Drummond GR. Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice. Br J Pharmacol 2015; 173:752-65. [PMID: 26103560 DOI: 10.1111/bph.13230] [Citation(s) in RCA: 135] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 05/16/2015] [Accepted: 06/13/2015] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND AND PURPOSE Inflammasomes are multimeric complexes that facilitate caspase-1-mediated processing of the pro-inflammatory cytokines IL-1β and IL-18. Clinical hypertension is associated with renal inflammation and elevated circulating levels of IL-1β and IL-18. Therefore, we investigated whether hypertension in mice is associated with increased expression and/or activation of the inflammasome in the kidney, and if inhibition of inflammasome activity reduces BP, markers of renal inflammation and fibrosis. EXPERIMENTAL APPROACH Wild-type and inflammasome-deficient ASC(-/-) mice were uninephrectomized and received deoxycorticosterone acetate and saline to drink (1K/DOCA/salt). Control mice were uninephrectomized but received a placebo pellet and water. BP was measured by tail cuff; renal expression of inflammasome subunits and inflammatory markers was measured by real-time PCR and immunoblotting; macrophage and collagen accumulation was assessed by immunohistochemistry. KEY RESULTS 1K/DOCA/salt-induced hypertension in mice was associated with increased renal mRNA expression of inflammasome subunits NLRP3, ASC and pro-caspase-1, and the cytokine, pro-IL-1β, as well as protein levels of active caspase-1 and mature IL-1β. Following treatment with 1K/DOCA/salt, ASC(-/-) mice displayed blunted pressor responses and were also protected from increases in renal expression of IL-6, IL-17A, CCL2, ICAM-1 and VCAM-1, and accumulation of macrophages and collagen. Finally, treatment with a novel inflammasome inhibitor, MCC950, reversed hypertension in 1K/DOCA/salt-treated mice. CONCLUSIONS AND IMPLICATIONS Renal inflammation, fibrosis and elevated BP induced by 1K/DOCA/salt treatment are dependent on inflammasome activity, highlighting the inflammasome/IL-1β pathway as a potential therapeutic target in hypertension.
Collapse
Affiliation(s)
- S M Krishnan
- Department of Pharmacology, Monash University, Clayton, Vic., Australia
| | - J K Dowling
- Centre for Innate Immunity and Infectious Diseases, MIMR-PHI Institute of Medical Research, Clayton, Vic., Australia
| | - Y H Ling
- Department of Pharmacology, Monash University, Clayton, Vic., Australia
| | - H Diep
- Department of Pharmacology, Monash University, Clayton, Vic., Australia
| | - C T Chan
- Department of Pharmacology, Monash University, Clayton, Vic., Australia
| | - D Ferens
- Department of Pharmacology, Monash University, Clayton, Vic., Australia
| | - M M Kett
- Department of Physiology, Monash University, Clayton, Vic., Australia
| | - A Pinar
- Centre for Innate Immunity and Infectious Diseases, MIMR-PHI Institute of Medical Research, Clayton, Vic., Australia
| | - C S Samuel
- Department of Pharmacology, Monash University, Clayton, Vic., Australia
| | - A Vinh
- Department of Pharmacology, Monash University, Clayton, Vic., Australia
| | - T V Arumugam
- Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.,School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea
| | - T D Hewitson
- Department of Nephrology, Royal Melbourne Hospital, Parkville, Vic., Australia
| | - B K Kemp-Harper
- Department of Pharmacology, Monash University, Clayton, Vic., Australia
| | - A A B Robertson
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
| | - M A Cooper
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia
| | - E Latz
- Institute of Innate Immunity, University Hospital, University of Bonn, Bonn, Germany.,Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA, USA.,German Center for Neurodegenerative Diseases, Bonn, Germany
| | - A Mansell
- Centre for Innate Immunity and Infectious Diseases, MIMR-PHI Institute of Medical Research, Clayton, Vic., Australia
| | - C G Sobey
- Department of Pharmacology, Monash University, Clayton, Vic., Australia.,Department of Surgery, Monash Medical Centre, Southern Clinical School, Monash University, Clayton, Vic., Australia
| | - G R Drummond
- Department of Pharmacology, Monash University, Clayton, Vic., Australia.,Department of Surgery, Monash Medical Centre, Southern Clinical School, Monash University, Clayton, Vic., Australia
| |
Collapse
|